UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Management of adverse events associated with idelalisib treatment: expert panel opinion

Leukemia & lymphoma, 2015-10, Vol.56 (10), p.2779-2786

2015

Volltextzugriff (PDF)

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

The New England journal of medicine, 2014-03, Vol.370 (11), p.997-1007

2014

Volltextzugriff (PDF)

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

The New England journal of medicine, 2014-03, Vol.370 (11), p.1008-1018

2014

Volltextzugriff (PDF)

PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases

Journal of medicinal chemistry, 2012-10, Vol.55 (20), p.8559-8581

2012

Volltextzugriff (PDF)

Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer

Proceedings of the National Academy of Sciences - PNAS, 2013-09, Vol.110 (37), p.15043-15048

2013

Volltextzugriff (PDF)

Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation

The Journal of cell biology, 2011-06, Vol.193 (7), p.1275-1288

2011

Volltextzugriff (PDF)

A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types

Biochemical journal, 2011-08, Vol.438 (1), p.53-62

2011

Volltextzugriff (PDF)

C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits

Gastroenterology (New York, N.Y. 1943), 2016-05, Vol.150 (5), p.1183-1195.e16

2016

Volltextzugriff (PDF)

p110α and p110β isoforms of PI3K signaling: are they two sides of the same coin?

FEBS letters, 2016-09, Vol.590 (18), p.3071-3082

2016

Volltextzugriff (PDF)

Idelalisib — A PI3Kδ Inhibitor for B-Cell Cancers

The New England journal of medicine, 2014-03, Vol.370 (11), p.1061-1062

2014

Volltextzugriff (PDF)

Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent

Cancer discovery, 2012-05, Vol.2 (5), p.425-433

2012

Volltextzugriff (PDF)

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia

Leukemia, 2017-01, Vol.31 (1), p.51-57

2017

Volltextzugriff (PDF)

Discovery of a Phosphoinositide 3‑Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856

Journal of medicinal chemistry, 2017-02, Vol.60 (4), p.1555-1567

2017

Volltextzugriff (PDF)

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models

European urology, 2015-06, Vol.67 (6), p.1177-1185

2015

Volltextzugriff (PDF)

Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER + Breast Cancer

Clinical cancer research, 2017-06, Vol.23 (11), p.2795-2805

2017

Volltextzugriff (PDF)

Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2‑((6-Amino‑9H‑purin-9-yl)methyl)-5-methyl-3‑(o‑tolyl)quinazolin-4(3H)‑one (IC87114) and Its Conformationally Restricted Analogs

Journal of medicinal chemistry, 2017-05, Vol.60 (10), p.4304-4315

2017

Volltextzugriff (PDF)

Human target validation of phosphoinositide 3‐kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor

Journal of thrombosis and haemostasis, 2012-10, Vol.10 (10), p.2127-2136

2012

Volltextzugriff (PDF)

MiR-126 overexpression inhibits high glucose-induced migration and tube formation of rhesus macaque choroid-retinal endothelial cells by obstructing VEGFA and PIK3R2

Journal of diabetes and its complications, 2017-04, Vol.31 (4), p.653-663

2017

Volltextzugriff (PDF)

Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model

Clinical cancer research, 2017-10, Vol.23 (19), p.5814-5823

2017

Volltextzugriff (PDF)

Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance

Scientific reports, 2015-06, Vol.5 (1), p.11634-11634, Article 11634

2015

Volltextzugriff (PDF)

Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease

Journal of medicinal chemistry, 2016-08, Vol.59 (15), p.7239-7251

2016

Volltextzugriff (PDF)

Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer

Cancer letters, 2015-04, Vol.359 (1), p.47-56

2015

Volltextzugriff (PDF)

Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3Kδ inhibitors

Bioorganic & medicinal chemistry letters, 2017-05, Vol.27 (9), p.1972-1977

2017

Volltextzugriff (PDF)

Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2‑((1S)‑1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro‑N‑methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2‑((1S)‑1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro‑N‑methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430)

Journal of medicinal chemistry, 2016-08, Vol.59 (15), p.7252-7267

2016

Volltextzugriff (PDF)

VEGF-mediated PI3K class IA and PKC signaling in cardiomyogenesis and vasculogenesis of mouse embryonic stem cells

Journal of cell science, 2011-06, Vol.124 (Pt 11), p.1819-1830

2011

Volltextzugriff (PDF)

1 – 25 von 127

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(118)
Mit Volltextzugriff
(113)

Publikationsform

Artikel
(127)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Management of adverse events associated with idelalisib treatment: expert panel opinion

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases

Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer

Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation

A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types

C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits

p110α and p110β isoforms of PI3K signaling: are they two sides of the same coin?

Idelalisib — A PI3Kδ Inhibitor for B-Cell Cancers

Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia

Discovery of a Phosphoinositide 3‑Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models

Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER + Breast Cancer

Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2‑((6-Amino‑9H‑purin-9-yl)methyl)-5-methyl-3‑(o‑tolyl)quinazolin-4(3H)‑one (IC87114) and Its Conformationally Restricted Analogs

Human target validation of phosphoinositide 3‐kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor

MiR-126 overexpression inhibits high glucose-induced migration and tube formation of rhesus macaque choroid-retinal endothelial cells by obstructing VEGFA and PIK3R2

Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model

Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance

Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease

Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer

Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3Kδ inhibitors

VEGF-mediated PI3K class IA and PKC signaling in cardiomyogenesis and vasculogenesis of mouse embryonic stem cells

Suchergebnisse filtern